Concarlo Holdings
Dr. Allamneni is a biopharma R&D expert with almost 20+ IND/IMPD submissions, 6 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates of various modalities. Forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. Impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Formerly with Turning Point, Jazz Pharmaceuticals and Genentech.
This person is not in any teams
This person is not in any offices
Concarlo Holdings
Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1.